Skip to main content
. Author manuscript; available in PMC: 2009 Oct 29.
Published in final edited form as: Drug Metab Dispos. 2008 May 19;36(8):1465–1469. doi: 10.1124/dmd.107.020065

Figure 2. Effect of rifampin or dexamethasone on CYP3A activity in African Americans who were stratified according to CYP3A5*1 allele carrier status.

Figure 2

(A) Rifampin significantly induced CYP3A activity in non-carriers (P = 0.0017) and carriers (P = 0.0008) of the CYP3A5*1 allele. (B) A significant increase in CYP3A activity was observed in CYP3A5*1 non-carriers after dexamethasone administration (P = 0.031). In contrast, an effect of dexamethasone on CYP3A activity was not detected in CYP3A5*1 carriers (P = 0.160). Open circles denote individual values. Closed bars denote the group mean.